Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Surgery for advanced stage lung cancer.

D H Grunenwald1

  • 1Thoracic Department, Institut Mutualiste Montsouris, Paris, France. thorax@imm.fr

Seminars in Surgical Oncology
|February 5, 2000
PubMed
Summary

Advanced non-small-cell lung cancer (NSCLC) treatment is complex. Induction therapy before surgery improves outcomes for Stage IIIb, while Stage IIIC and IV are generally non-surgical.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of surgery in non-small-cell lung cancers.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer.

The Journal of thoracic and cardiovascular surgery·2001
Same author

Transmanubrial approach reproposed.

The Annals of thoracic surgery·1999
Same author

Pneumonectomy for lung metastases: indications, risks, and outcome.

The Annals of thoracic surgery·1999

Area of Science:

  • Thoracic Surgery
  • Medical Oncology
  • Pulmonology

Background:

  • Therapeutic strategies for advanced non-small-cell lung cancer (NSCLC) remain controversial.
  • Current 5-year survival rates after surgery for Stage IIIa disease are below 15%.
  • Induction chemotherapy followed by surgery has shown significant benefits compared to surgery alone.

Purpose of the Study:

  • To clarify therapeutic options for non-small-cell lung cancer (NSCLC) by refining the staging system for advanced disease.
  • To redefine resectability criteria for T4 tumors and N2 nodal involvement.
  • To propose a new three-tiered staging system (IIIA, IIIB, IIIC) for Stage III NSCLC.

Main Methods:

  • Review and analysis of existing data on surgical resection and induction therapies for advanced NSCLC.
  • Evaluation of the French staging system's subcategories for N2 involvement (mN2 vs. cN2) and T4 tumors (T4(1) vs. T4(2)).
  • Proposal of a revised staging system for Stage III NSCLC based on prognostic and therapeutic subcategories.

Main Results:

  • Stage IIIb tumors can be categorized as potentially resectable or definitively non-resectable, with some becoming operable after induction chemoradiotherapy.
  • The proposed French staging system divides Stage III into IIIA (primary surgery), IIIB (induction treatment), and IIIC (non-surgical).
  • T4 tumors are classified as T4(1) (potentially resectable) or T4(2) (definitively non-resectable).

Conclusions:

  • A revised staging system for Stage III NSCLC can clarify therapeutic pathways.
  • Stage IIIA is suitable for primary surgery, Stage IIIB requires induction treatment, and Stage IIIC necessitates non-surgical approaches.
  • Further clinical trials are needed to refine resectability criteria and optimize local control through surgery.

Related Experiment Videos